Aggregating Data Hides Cancer Disparities Affecting Asian and NHPI Patients in the US
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma. -
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment. -
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease. -
ASH 2022: New Findings in CLL
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
HEMATOLOGIC CANCER NEWS
Epcoritamab Shows Promise in Large B-Cell Lymphoma
Risk of Suicide Highest in the First 6 Months After a Cancer Diagnosis
Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
Loading... 
Loading...